Related Experiment Videos
Biological characterization of a novel antitumor quinolone
J J Clement1, N Burres, K Jarvis
1Abbott Laboratories, Abbott Park, Illinois 60064-3500.
Abstract:
A-84441, a potent new antitumor quinolone, was active in vitro and in vivo against murine and human tumors. A-84441, a prodrug, was comparable in potency to the parent compound with an IC50 range of 0.03-0.49 microgram/ml against a panel of murine and human tumor cell lines. The parent compound bound mammalian DNA in a magnesium-dependent manner and caused inhibition of DNA and RNA synthesis. A-84441 produced a significant increased life span and cures in three lines of i.p. implanted murine tumors. A-84441 was active against seven of nine solid tumors including s.c. murine tumors and human tumor xenografts. The compound appeared to be more active when administered i.v. compared to i.p. injection. Antitumor efficacy was little effected by treatment schedule, although multiple divided dosing was generally more effective than single dose treatment. A-84441 was over 10-fold-more active against murine leukemic cells than against normal murine bone marrow cells. The acute toxicity of A-84441 following single or multiple dosing ranged between 11 and 50 mg/kg dependent on schedule of administration when given by i.v. or i.p. route. The agent had no apparent toxicity or efficacy when administered p.o.
Insights
A novel antitumor quinolone, A-84441, demonstrated significant efficacy against various murine and human tumors in vitro and in vivo. This prodrug showed potent activity and improved survival rates in preclinical cancer models.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- A-84441 is a novel quinolone derivative investigated for its antitumor properties.
- Quinolones are known for their DNA-binding capabilities, suggesting a potential mechanism for anticancer activity.
Purpose of the Study:
- To evaluate the in vitro and in vivo antitumor activity of A-84441 against a range of murine and human tumors.
- To assess the potency, efficacy, toxicity, and optimal administration of A-84441.
Main Methods:
- In vitro assays were performed to determine the IC50 values against tumor cell lines.
- In vivo studies involved administering A-84441 to mice with implanted tumors (intraperitoneal and subcutaneous).
- Toxicity assessments were conducted following various dosing schedules and routes of administration.
Main Results:
- A-84441 exhibited potent activity with IC50 values ranging from 0.03-0.49 microgram/ml against tumor cell lines.
- The compound significantly increased lifespan and achieved cures in murine tumor models, showing activity against seven of nine solid tumors.
- A-84441 demonstrated a favorable therapeutic index, being over 10-fold more active against leukemic cells than normal bone marrow cells, with acute toxicity observed at 11-50 mg/kg.
Conclusions:
- A-84441 is a potent antitumor agent with broad-spectrum activity against murine and human cancers.
- Intravenous administration and multiple divided doses appeared more effective, while oral administration showed no efficacy or toxicity.
- The compound warrants further investigation as a potential therapeutic agent for various cancers.